Constitutive Neutrophil Apoptosis: Regulation by Cell Concentration via S100 A8/9 and the MEK – ERK Pathway

Mizhir Atallah, Alon Krispin, Uriel Trahtemberg, Sandrine Ben-Hamron, Amir Grau, Inna Verbovetski, Dror Mevorach*

The Laboratory for Cellular and Molecular Immunology, Department of Medicine, Rheumatology Research Centre, Hadassah-Hebrew University Medical Center Jerusalem, Jerusalem, Israel

Abstract

Programmed cell death (PCD) is a fundamental mechanism in tissue and cell homeostasis. It was long suggested that apoptosis regulates the cell number in diverse cell populations; however, no clear mechanism was shown. Neutrophils are the short-lived, first-line defense of innate immunity, with an estimated t = 1/2 of 8 hours and a high turnover rate. Here we first show that spontaneous neutrophil constitutive PCD is regulated by cell concentrations. Using a proteomic approach, we identified the S100 A8/9 complex, which constitutes roughly 40% of cytosolic protein in neutrophils, as mediating this effect. We further demonstrate that it regulates cell survival via a signaling mechanism involving MEK-ERK via TLR4 and CD11B/CD18. This mechanism is suggested to have a fine-tuning role in regulating the neutrophil number in bone marrow, peripheral blood, and inflammatory sites.

Citation: Atallah M, Krispin A, Trahtemberg U, Ben-Hamron S, Grau A, et al. (2012) Constitutive Neutrophil Apoptosis: Regulation by Cell Concentration via S100 A8/9 and the MEK – ERK Pathway. PLoS ONE 7(2): e29333. doi:10.1371/journal.pone.0029333

Editor: Marcello G. Bonini, University of Illinois at Chicago, United States of America
Received June 10, 2011; Accepted November 25, 2011; Published February 17, 2012

Copyright: © 2012 Atallah et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This research was partially supported by a grant from the Hadassah-Hebrew University Medical Center. No additional external funding received for this study. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: mevorachd@hadassah.org.il

Introduction

Programmed cell death (PCD) is a fundamental mechanism in tissue and cell homeostasis, long thought to regulate cell number in diverse populations. In developmental biology, PCD provides an efficient mechanism for eliminating unwanted cells, as shown in studies with the nematode Caenorhabditis elegans [1]. Of the 1090 somatic cells formed during the development of an adult hermaphrodite, exactly 131 die, demonstrating the morphological features of apoptosis. In the mammalian immune system, clonal triggering results in lymphocyte proliferation followed by activation-induced cell death that ensures T cells will return to their original concentration, adding only a negligible number of memory cells [2].

Few studies in the human immune system have questioned the mechanism of constitutive leukocyte blood concentration regulation via PCD. In humans, neutrophils are the short-lived, first-line defense of innate immunity, with estimated t = 1/2 of 8 hours and a high turnover rate [3]. These cells, which represent 50–60% of the circulating leukocytes in normal conditions, are considered terminally differentiated cells. They are rapidly recruited and accumulate in the early phase of inflammation.

Under normal physiological conditions, absent triggers initiating neutrophil exit from the blood pool into tissues, human blood neutrophil counts are determined by the balance between neutrophil hematopoiesis, neutrophil mobilization from the bone marrow, the marginal pool, spontaneous constitutive PCD, and phagocytosis of apoptotic neutrophils. Human neutrophils are generated in bone marrow, mainly under the control of G-CSF and additional cytokines and growth factors, including M-CSF, GM-CSF, IL-6, IL-3 (reviewed by Metcalf [4]), and possibly IL-17 and IL-23 [3], as well as IL-22.
of Fas-induced death remains controversial [11,18–20]. In addition, neutrophil life expectancy can be modulated by various mediators (G-CSF, GM-CSF, IL-1β, IFN-gamma, and LPS [21–25]) or functional events such as transmigration across the endothelium [26].

Despite our growing understanding of molecular control of neutrophil PCD, it remains unclear how specific neutrophil blood concentration is maintained. We hypothesized that cell concentration might serve as a neutrophil count regulator via a feedback mechanism affecting PCD. We examined the in vitro effect of cell number on spontaneous neutrophil PCD, and demonstrated that neutrophil PCD is strongly influenced by cell concentration. We hypothesized that secreted molecules mediate this effect, and used a proteomic approach, which showed that constitutive spontaneous neutrophil PCD is regulated by cell concentration through molecules released during neutrophil PCD. We further show that the S100 A8/9 complex is a primary regulatory molecule regulating cell survival via CD11b/CD18 and TLR4, and through a signaling mechanism involving MEK-ERK.

Materials and Methods

Materials

Cell culture medium consisted of RPMI 1640 (Invitrogen-Gibco, NY) supplemented with 1% L-glutamine and 1% penicillin/streptomycin (Biological Industries, Kibbutz Beit-Haemek, Israel). The APOPTEST-FITC Kit containing Annexin V-FITC was obtained from Nexins Research B.V. (Hoeven, The Netherlands) or from MBL International (Cambridge, MA). Propidium iodide (PI) was from Molecular Probes (Eugene, OR). Recombinant proteins S100A8 and S100A9, and blocking antibodies were generously supplied by Dr. Philippe A. Tessier. (Laval University, Quebec, Canada). The pan-caspase inhibitor zVAD-fmk was purchased from R&D systems (Minneapolis, MN).

Mouse anti-human CD36-PE, mouse anti-human CD11b-PE, and isotype control IgG1-PE were obtained from Serotec (Oxford, UK), and isotype control mouse IgM-PE from Dako (Glostrup, Denmark).

DiOC6(3) (3,3-dihexyloxocarbocyanine iodide) was purchased from Sigma-Aldrich (St. Louis, MO). MEK inhibitor PD98059 was purchased from Cell Signaling (Danvers, MA).

Antibody against the complex S100A8/9 for flow cytometry analysis was purchased from Abcam (Cambridge, MA).

For blocking assays, rabbit polyclonal anti-S100A8 and anti-S100A9 were generously supplied by Dr. Philippe A. Tessier, and blocking antibody against CD11b (BioLegend, San Diego, CA) was used at different dilutions as indicated. Rabbit serum was obtained from Jackson Laboratories (Jackson ImmunoResearch, West Grove, PA).

Cell isolation and culturing

Blood neutrophils were isolated from fresh buffy coats obtained from healthy donors. RBCs were sedimented by adding 6% hetastarch in 0.9% NaCl solution (Stem Cell Technologies, Vancouver, Canada) and kept at 25°C for up to 45 min. The leukocyte-rich upper layer of the suspension was then collected and centrifuged on a density gradient with Ficoll-Paque (Amerham Biosciences, Uppsala, Sweden). Residual erythrocytes were removed by hypotonic lysis. Neutrophils were maintained in suspension, at different concentrations as indicated, in RPMI 1640 medium, 1% L-glutamine, and 1% penicillin/streptomycin, in 24-well plates at 37°C, in a humidified incubator containing 5% CO2. Cells were >95% neutrophils as determined by morphological analysis and >99% viable as determined by Trypan blue dye exclusion.

Apoptosis assessment.

Apoptosis assessment was performed as previously described [27] (For detailed method see – Methods S1).

Supernatant transfer

Neutrophils were suspended at concentrations of either 0.5×10^6/ml or 16×10^6/ml, for different times as indicated, at 37°C/5% CO2. After culturing, the supernatants of the high concentration were collected and added to fresh neutrophils from the same donor at concentration of 0.5×10^6/ml and vice versa. The neutrophils were then allowed to undergo constitutive spontaneous PCD and apoptosis was detected as described.

Transmission electron microscopy

Cells were fixed in 2% glutaraldehyde in cacodylate buffer (0.1M, PH 7.2–7.4) and washed three times in the same buffer. Cells were then postfixed in 1% OSO4 for 1 h at room temperature, washed in cacodylate buffer, dehydrated in gradient series of ethanol (25%, 50%, 75%, 95%, 100% x2), treated with propylene-oxide for 20 min (2 changes), and embedded in Araldite Resin. Thin sections were prepared with an ultramicrotome and examined at an accelerated voltage of 100kV by transmission electron microscope (CM12, Philips, Eindhoven, The Netherlands).

Proteomic (SDS-PAGE and MS) and Western blotting.

Proteomic (SDS-PAGE and MS) and Western blotting were performed as previously described [28] (For detailed method see – Methods S1).

Transfection

The two cell lines, Chinese hamster ovary (CHO), and CHO stably transfected with complement receptor CR3, were kindly provided by Drs. R.R. Ingalls and D.T. Golenbock, Boston Medical Center, Boston, MA.

Leukocyte adhesion deficiency deficiency patients and controls

LAD patients signed an informed consent approved by the Ethics Committee of Hadassah-Hebrew University Medical Center. Controls consisted of age- and gender-matched healthy donors, who signed an informed consent. Blood (10 ml) from healthy donors and heparinized blood (10 ml) from patients was drawn and evaluated on the same day.

Detection of intracellular phosphorylated ERK by flow cytometry

For the assessment of phosphorylation of the ERK, freshly isolated neutrophils were treated as indicated and prepared for intracellular staining. Cells were washed with PBS, fixed with 2% formaldehyde for 10 min at 37°C, and permeabilized with 0.9% methanol for 30 min on ice. Cells then were rinsed and incubated for 10 min at RT in PBS containing 0.5% BSA (for blocking), and stained with either mouse anti-human phospho-p44/42 MAPK alexa fluor 488 (Cell Signaling Technology) or isotype control mouse IgG1 alexa fluor 488 (BioLegend).

Statistical analysis

The Student’s t test and one-way analysis of variance (ANOVA) were used to compare mean data. The Kolmogorov-Smirnov test was used to analyze flow cytometry results. Differences were considered statistically significant for p<0.05.

Results

The effect of cell concentration on constitutive spontaneous neutrophil PCD

We assumed constitutive spontaneous PCD requires one or more autoregulatory negative feedback mechanisms exerted by dying neutrophils that affect survival rates of the remaining cells
Without this effect, one might assume that PCD increases at higher concentrations due to competition for nutrition and other ingredients. We designed an experiment to examine the effect of various cell concentrations in the physiological range (peripheral blood neutrophil concentration \(\sim 2-6 \times 10^6/\text{ml}\)) on the constitutive spontaneous PCD rate. A higher apoptotic cell concentration had a protective anti-apoptotic effect, and the rate of neutrophil PCD was inversely proportional to cell concentration, indicating an anti-apoptotic effect (Fig. 2A). Whereas following 12\(h\) of spontaneous constitutive PCD only 5\% of cells were still alive at a concentration of \(0.5 \times 10^6\) neutrophils/ml, in conditions of 32\(\times\)fold concentration, at \(16 \times 10^6\) neutrophils/ml, more than 40\% of the cells were still alive, as shown by Annexin V and PI negative staining (Fig. 2B) and verified by mitochondrial potential loss studies (not shown), both methods of apoptosis detection indicated early apoptosis state. This phenomenon was further emphasized using cell count. There was loss of over 50\% of cells through constitutive spontaneous PCD at concentrations of \(--0.5 \times 10^6/\text{ml}\) for 12\(h\) (Fig. 2C), and this loss decreased in proportion to increasing cell concentrations up to \(16 \times 10^6/\text{ml}\). At concentrations above \(16 \times 10^6/\text{ml}\), there was a decline in cell number and a prodeath effect, probably as a result of competition for nutrition and other ingredients.

Thus, at physiological concentrations of neutrophils, there was an anti-apoptotic effect at higher neutrophil concentrations. We termed this a “community effect” — neutrophils are encouraged to live longer as their community is enlarged.

**Factors mediating the community effect are present in the supernatant**

In order to determine whether the factor(s) responsible for the community anti-apoptotic effect are found in the supernatant, we exchanged media obtained from low- and high concentrations of constitutive spontaneous neutrophil PCD. The supernatants from high concentrations were collected and used as media for low-concentration constitutive spontaneous neutrophil PCD of the same donor, and the supernatants of low concentrations were used as media for constitutive spontaneous neutrophil PCD at high cell concentration. Media based on high-concentration PCD donors (\(16 \times 10^6\) cells/ml) rescued cells undergoing constitutive spontaneous neutrophil PCD at low concentration (\(0.5 \times 10^6\) cells/ml) from apoptosis, as compared with normal medium (Fig. 3A). High-concentration medium increased the rate of viable cells from 9\% (upper left panel, Fig. 3B) to 31\% (upper right panel, Fig. 3B). In the opposite experiment, low-concentration media had no effect on survival in high cell concentration samples (left and right lower panel, Fig. 3B).
Presented is the mean ± SD of 3 experiments. A. Neutrophils underwent spontaneous constitutive PCD for 12 h at cell concentrations ranging from 0.5 × 10^6/ml up to 50 × 10^6/ml. (The physiological blood concentration is 2–6 × 10^6/ml) Apoptosis was assessed by Annexin V-FITC and PI staining, as described in Materials and methods. Data represents the mean ± SD of 3 experiments. B. Sample dot plots of Annexin V-PI staining of neutrophils undergoing spontaneous constitutive PCD for 12 h in (a) 0.5 × 10^6/ml, and (b) 16 × 10^6/ml. The percentage of viable, early (Annexin V^-/PI^-) and late (Annexin V^-/PI^+) apoptotic cells is indicated within the respective quadrants. C. Survival of neutrophils undergoing spontaneous constitutive PCD, based on cell counts. Data presented is the mean ± SD of 3 experiments. doi:10.1371/journal.pone.0029333.g002

Panels, Fig. 3B. All these experiments were based on at least three experiments each and results with Annexin V were verified using mitochondrial potential loss studies.

These results suggest that in the presence of high neutrophil concentrations, anti-apoptotic factor(s) are secreted and provide a survival signal to the viable neutrophil community.

Proteomic analysis of the supernatants and identification of S100A8 and S100A9 as candidate molecules for mediation of the community anti-apoptotic signal

We used a differentially displayed proteomic approach, as we have previously described [28], to search for secreted factor(s) in the supernatant that may be responsible for the “community effect” on neutrophil survival.

The secreted proteomes of neutrophils undergoing constitutive spontaneous neutrophil PCD at high concentrations (16 × 10^6/ml) and low concentrations (0.5 × 10^6/ml) were collected and compared by SDS-PAGE and Coomassie staining. Differentially expressed proteins were further analyzed by mass spectrometry (MS). Expression of two proteins, ~10 KD and ~14 KD, represented the primary difference between the supernatants (Fig. 3C). Both were expressed at significantly greater levels in supernatant of cells cultured at high neutrophil concentrations, versus supernatant of cells cultured at low concentrations, despite protein normalization according to cell number and equal protein loading in the gel. Proteins were further identified by MS as S100A8 and S100A9, as the best candidates for the community effect (Table 1). The experimental approach was designed to use 2D gel; however, 1D gel identified with high certainty two candidate proteins that were chosen for further functional studies.

Functional studies suggest that S100A8-9 mediates the community effect

We sought to verify S100A8 and A9 mediated the community anti-apoptotic effect using recombinant human S100A8 and A9 (kindly provided by Philippe A. Tessier, Laval University, Quebec, Canada) added to neutrophils undergoing spontaneous constitutive PCD. Increased S100A9 and S100A8/9 levels had a dramatic rescue effect on the number of neutrophils undergoing spontaneous constitutive PCD at low cell concentrations (*p < 0.05), paralleling the rescue effect of the high cell concentration supernatant (Fig. 4A). Survival increased by more than 150% ± 33% in the presence of 3 µg/ml of S100A8/9, as measured by Annexin V and PI (**p < 0.02). The survival effect of S100A9 and the S100A8/9 complex was more prominent compared to S100A9 alone. Only S100A9 had an effect already at a concentration of 1 µg/ml. Nonetheless, S100A8 in higher concentrations of 2 and 5 µg/ml also had a significant rescue effect (Fig. 4A). To further verify the anti-apoptotic effect of S100A8/9, we measured mitochondrial transmembrane potential as an additional early PCD evaluation, demonstrating a perfect correlation to the Annexin V-PI measurements (Fig. 4B).

We sought to verify whether S100A9 and S100A8/9 effects are blocked with specific antibodies, using rabbit polyclonal antibodies raised against human S100A8 or S100A9. Antisera were used at a range of dilutions between 1/10 and 1/10,000, as indicated. Adding the antibodies reduced neutrophil survival by 30–40% in various dilutions (Fig. 4C), compared to control antibodies, and induced accelerated PCD similar to that seen in spontaneous constitutive PCD in low cell concentration supernatants. Mitochondrial transmembrane potential as an additional early PCD evaluation, demonstrated a perfect correlation to the Annexin V-PI measurements. This further supports a role for S100A8/9 as the main factor triggering the community anti-apoptotic effect.

S100A8/9 does not mediate the community effect via McI1, A1, the bcl-2 protein family, or survivin

We examined the expression of different members of the PCD intrinsic pathway, focusing on those known to be important in neutrophil PCD. McI1, an anti-apoptotic member, was expressed by freshly isolated neutrophils (see Figure S3), and expression was still detected during spontaneous constitutive apoptosis. Adding S100A8/9 did not change McI1 expression. A1 protein has also been found to be expressed in neutrophils [13, 15]. We found that A1 was expressed by freshly isolated neutrophils, with expression dramatically decreased during constitutive spontaneous PCD (see Figure S3). Adding S100A8/9 did not prevent decreased A1 expression. Bcl-xl was found to be expressed by freshly isolated neutrophils. Expression was neither decreased by constitutive spontaneous PCD, nor increased by adding S100A8/9. We also examined the expression of BcI2 and survivin proteins. These two proteins were not expressed by freshly isolated neutrophils or during induction of
constitutive spontaneous PCD, which is consistent with observations that peripheral blood neutrophils don’t express these two proteins [11–14,16].

In conclusion, we could not identify an anti-apoptotic mechanism in the main intrinsic pathway players of neutrophil PCD.

The survival effect of S100A8/9 involves the MEK-ERK signaling pathway, and is partially mediated through TLR4 and the integrin CD11b/CD18

S100A8 and A9 specific receptors have not yet been identified. However, Vogl et al demonstrated that S100A8 specifically interacts with the TLR4-MD2 complex [29], and Newton RA et al suggested that a pertussis toxin-sensitive G-coupled protein receptor could be the S100A9 receptor [30]. S100A8 and A9 have been shown to exert their effects via CD36 and CD11b/CD18 (Mac-1) [30–32]. CD11b/CD18 is well expressed in freshly isolated neutrophils, but CD36 is not (Fig. 5A, upper panel). Furthermore, CD11b/CD18 was suggested as a pro-apoptotic integrin [33,34].

Following spontaneous constitutive PCD, we detected a homogeneous decrease in neutrophil expression of CD11b/CD18. Gating apoptotic (Annexin V-positive) versus non-apoptotic...
Table 1. Proteins identified by mass spectrometry.

| Peptide sequence | Protein score (Mowse) | Identified protein | Remarks |
|------------------|-----------------------|-------------------|---------|
| MTCKMQSER       | 330                   | S100A9            | Reported role in inflammation |
| NIETINTFH       |                       |                   |         |
| QYSVKLGHPD      |                       |                   |         |
| TLNQGEFKEL      |                       |                   |         |
| VRIKDQENFLK     |                       |                   |         |
| RENKNEVIE       |                       |                   |         |
| HIMEDLTDNA      |                       |                   |         |
| DKQLSFEFEI      |                       |                   |         |
| MLMAR1         |                       |                   |         |
| TWASHEKMHIEQGDEG|                       |                   |         |
| FPHHHHPG          |                       |                   |         |
| EGTP             |                       |                   |         |
| MLTELEKAN       | 458                   | S100A8            | Reported role in inflammation |
| S1DLYHVKYS      |                       |                   |         |
| LIKGNPHAVY      |                       |                   |         |
| RDDDKKLET       |                       |                   |         |
| ECPQYIRKKG      |                       |                   |         |
| ADVWFKELDI      |                       |                   |         |
| NTGDAGNVFQSE    |                       |                   |         |
| FLIIVKMAW       |                       |                   |         |
| QTPTKAMKKA      |                       |                   |         |
| TKSS            |                       |                   |         |
| MWHLTFEEKS      | 207                   | beta globin chain variant |
| AVLWLGKRNV      |                       |                   |         |
| VDVEGGGAELG     |                       |                   |         |
| RLVVYPWPTQ      |                       |                   |         |
| RFESFGDLS       |                       |                   |         |
| TDPAVMGMPK      |                       |                   |         |
| VKAHGHKVG      |                       |                   |         |
| AFSDGHLHLD      |                       |                   |         |
| NLKGIATLIS      |                       |                   |         |
| ELHCDKRLVYD     |                       |                   |         |
| PENFRRNLV       |                       |                   |         |
| LCVLHALHFGG     |                       |                   |         |
| KKFETTPVQA      |                       |                   |         |
| YQKVWAGAYAN     |                       |                   |         |
| ALAHIKYH        |                       |                   |         |
| VLSPADKTNV      | 94                    | Chain C, T State Human Hemoglobin [alpha V96w] |
| KAAWGGVGAH      |                       |                   |         |
| AGYESGAEALE     |                       |                   |         |
| RMFLSFPPTK      |                       |                   |         |
| TYPYFIDLSH      |                       |                   |         |
| GASAVKGYHKG     |                       |                   |         |
| KVAADLANAV      |                       |                   |         |
| AHVYDMPNAL      |                       |                   |         |
| SALSDLHAKH      |                       |                   |         |
| LIRVDQWNFLK     |                       |                   |         |
| LSHCLVTLA       |                       |                   |         |
| AHPDAPFTPA       |                       |                   |         |
| VHASLGDIFLA      |                       |                   |         |
| SVSTVLTSKY R    |                       |                   |         |
| RRPDFCLEPP      | 113                   | Aprotinin         | Protease inhibitor (synthetic) |
| YTGPCKRAIRI     |                       |                   |         |
| RYFYNAKAGL      |                       |                   |         |
| CQTFVYGGCR      |                       |                   |         |
| AKNRNFKSAE      |                       |                   |         |
| DCMTCCGGA       |                       |                   |         |

Analysis of proteins identified by mass spectrometry. Sequences corresponding to the identified peptides are bolded. Score was based on molecular weight search (MOWSE) peptide-mass database. The results identified S100A8 and S100A9 as candidate proteins.

doi:10.1371/journal.pone.0029333.t001

Figure 4. Effect of S100A9 and S100A8 on neutrophil apoptosis. A. S100A9 and S100A8 add-in experiments. Varying concentrations of S100A9, S100A8, and the S100A8/9 complex were added to supernatants of neutrophils undergoing spontaneous constitutive PCD at a concentration of 0.5×10⁶/ml. After 10 hours apoptosis was evaluated using Annexin V-FITC and mitochondrial staining. Data is presented as mean ± SD of Annexin V-PI staining (* p<0.05, ** p<0.02). B. S100A9 and S100A8 add-in experiments. A representative sample of Annexin V-FITC and mitochondrial staining. Neutrophils undergoing spontaneous constitutive PCD without (a and c) or with (b and d) the addition of 2 μg/ml S100A8/9. Cells were stained either with Annexin V-FITC (a and b) or with DiOC₆ (c and d), as well as PI (a, b, c, d) and assessed by flow cytometry. Dot plots are representative of 6 experiments. C. The effect of anti-S100A8 and A9 on add-in experiments. Neutrophils undergoing spontaneous constitutive PCD at a concentration of 0.5×10⁶/ml for 12h, with rabbit polyclonal antibody dilutions of 1:100, 1:1000, and 1:10,000 against S100A9 and S100A8, were then treated with 2 μg/ml S100A8/9 complex. Rabbit serum at the same dilutions of 1:100, 1:1000, and 1:10,000 was used as a control. Apoptosis was assessed using Annexin V-FITC and PI staining. Percentages of viable, early-, and late apoptotic cells are indicated within the respective quadrants. Dot plots are representative of 6 experiments.

doi:10.1371/journal.pone.0029333.g004
Figure 5. The survival effect of S100A8/9 is mediated through CD11b/CD18 and TLR4. A. Expression of CD11b on neutrophils. Upper panel. Freshly isolated neutrophils were transfected with the constructs in (Fig. 5B) as indicated in Materials and methods. B. Expression of CD11b was determined by intracellular staining with anti-CD11b and a FITC-conjugated secondary antibody. C. The effect of CD11b on the survival of S100A8/9 complex-exposed neutrophils. Neutrophils were incubated with 50 μM CD11b-FITC for 1 h, before addition of S100A8/9 complex. D. The effect of CD11b on the survival of S100A8/9 complex-exposed neutrophils. Neutrophils were incubated with 50 μM CD11b-FITC for 1 h, before addition of S100A8/9 complex.

Extracellular signal-regulated kinase (ERK), one of the mitogen- activated protein kinase (MAPK) family, is involved in integrin signaling and Toll-like receptors in general. It appears to mediate signals promoting cell proliferation, differentiation, and survival, as reviewed by Roux, et al [35]. We assessed the role of ERK in the neutrophil S100A8/9 survival effect using intracellular staining of phosphotyrosine ERK. Neutrophils exposed to S100A8/9 for 10 min showed more than a threefold increase in phosphorlation of the ERK kinase (Fig. 6A). This activation continues to a lesser extent following 30 and 60 min exposure. Furthermore, the inhibitor PD98059 (MEK inhibitor) reduced ERK phosphorylation by more than 50% (Fig. 6B) and abolished the S100A8/9 survival effect by 50%–100% at various concentrations (Fig. 6C), suggesting that the S100A8/9 complex survival effect involves the MEK-ERK signaling pathway.

Apoptotic neutrophils are not activated neutrophils

As S100A8/9 was mainly reported thus far to be released during inflammation (see discussion), it may be attributed to release due to neutrophil activation. We wanted to further verify that apoptotic neutrophils are not activated due to extracellular or in vitro effect. Therefore we analyzed three surface molecules that are upregulated upon neutrophil activation and downregulated upon neutrophil PCD. In figures S1 and S2, CD16 and CD62L, both markers of neutrophil activation showed clear down regulation in the examined neutrophils, in correlation to apoptotic state [36]. In addition CD11b, a third molecule, that is upregulated upon activation was downregulated in apoptotic neutrophils releasing S100A8 and S100A9 (see Figure 5). Taken together, S100 A8 and S100A9 were released in the context of apoptotic neutrophil death in non activated neutrophils.

Discussion

Neutrophils are responsible for the body’s rapid and effective response to infection or injury [37]. Efficient function necessitates an optimal balance between a sufficient number of blood neutrophils, response to stimuli, and transmigration properties, on one hand, against regulation of the termination of a neutrophil-mediated inflammatory response on the other. Thus, control of neutrophil turnover in the bone marrow and circulation, and at inflammatory sites, is key to both homeostasis and inflammation. PCD plays a critical role in neutrophil homeostasis for an optimal functioning in the human body. Polymorphonuclears comprise approximately 75% of all nucleated cells in the
hematopoietic compartment of the newborn marrow, with the majority being neutrophils. Already in the bone marrow, large-scale neutrophil death and removal of neutrophils by phagocytes are seen [38]. Yet, the major regulator of blood neutrophil counts, as well as neutrophil counts at inflammatory sites, is PCD, which allows only a short life span, with modulation according to needs such as inflammation.

Here we show that the S100 A8/9 complex regulates neutrophil number and PCD in response to neutrophil concentration, by an anti-apoptotic effect. S100A9 (MRP14) and S100A8 (MRP8) constitute roughly 40% of the cytosolic protein in neutrophils; their pure abundance implies an important role in neutrophil functions. However, our understanding of the mechanisms implicating both molecules in neutrophil/monocyte physiology remains incomplete, as reviewed by Nacken, et al [39].

S100A9 and S100A8 readily form hetero- and homodimeric, trimeric, and tetrameric complexes, but apparently also exert specific functions as monomers. It has been suggested that S100A9 plays a prominent role in leukocyte trafficking and arachidonic acid metabolism, and elevated S100A9 and S100A8 levels are found in body fluids of inflamed tissues. When neutrophils undergo PCD, they release S100A8/9, which partially protects surrounding neutrophils from PCD, a mechanism that may be of crucial importance in fine-tuning neutrophil concentrations in the bone marrow and blood, and in inflammatory sites. This finding is supported by the decrease in bone marrow neutrophils in S100A9-deficient mice [40], and the accumulation of S100A8/9 at inflammatory sites, where prolonged survival of neutrophils is usually needed for chemotaxis and neutrophil adhesion [32].

As shown in figure 5A and supplemental figures 1 and 2, apoptotic neutrophils were not activated and their S100A8 and S100A9 release was associated with PCD and not inflammation or activation.

S100A8 deficiency is lethal [41], thus further research to gain understanding of the role of S100A8/9 is partially limited to animal models. By prolonging neutrophil life, S100A8/9 accumulation could be also a contributing mechanism to autoimmune conditions and the development of chronic inflammation or acute sterile danger-related inflammation. In conditions such as gout, monosodium urate monohydrate crystals induce the release of S100A8/A9 from neutrophils [42] and allow inflammatory attack by prolonging neutrophil life. High S100A8/9 levels were found in chronically inflamed joints of patients with rheumatoid arthritis [43].

Figure 6. Effects of the S100A8/9 complex are mediated through the MAPK-ERK pathway. A. Phosphorylation of MAPK following exposure to S100A8/9. Freshly isolated neutrophils with or without treatment with 2 µg/ml S100A8/9 for various times as indicated, and then prepared for intracellular staining with mouse anti-human phospho-p44/42 MAPK alexa fluor 488 (gray) or isotype control (black), as described in Materials and methods. In the presence of S100A8/9, phosphorylation was increased by 3.22-fold after 10 min (\( p<0.001 \)), 1.5-fold after 30 min (\( p<0.001 \)), and decayed at 60 min (\( p<0.001 \)). Histograms are representative of 3 independent experiments. B. Reduced phosphorylation of MAPK following exposure to S100A8/9 in the presence of PD98059, a MAPK phosphorylation inhibitor. Freshly isolated neutrophils were treated with the inhibitor PD98059 or with DMSO as a control for 30 min, and then treated with 2 µg/ml S100A8/9. Cells were then harvested and prepared for intracellular staining of phospho-p44/42 MAPK (gray) or isotype control (black), as described in Materials and methods. Treatment with PD98059 inhibitor reduced phosphorylation caused by the S100A8/9 complex (\( p<0.001 \)). Histograms are representative of 3 experiments. C. Effect of the S100A8/9 complex in the presence of MAPK-ERK inhibitor. The effect of S100A8/9 was assessed in the presence of PD98059. Freshly isolated neutrophils were treated with varying combinations and concentrations of DMSO (white bars), S100A8/9 complex (gray bars), or S100A8/9 complex with PD98059 (black bars), as indicated, for 30 min before adding S100A8/9. Neutrophils were allowed to undergo constitutive spontaneous PCD. Results represent the percentage of viable cells according to Annexin V-FITC and PI staining. Data is representative of 3 experiments (\( p<0.001 \)). doi:10.1371/journal.pone.0029333.g006
Our study also proposes an additional possible mechanism for neutropenia following chemotherapy, suggesting that low neutrophil concentration may be further aggravated due to accelerated PCD, induced at low neutrophil concentrations. This hypothesis needs further investigation.

We were also able to gain a better understanding of the mechanism enabling S100A8/9 function. S100A8/9 clearly upregulates and binds to CD11b, previously shown to be a major regulator of neutrophil PCD [44], with possible anti- or pro-apoptotic effect. However, as shown here, this effect was retained in CD11b-deficient neutrophils, indicating additional mechanisms such as TLR4.

Indeed, blocking TLR4 partially abrogated the S100A8/9 survival effect, suggesting that S100A8/9 is an endogenous TLR4 ligand mediating survival. It has been shown that the TLR4 agonist LPS and others inhibit neutrophil apoptosis [12,45]. Here we show for the first time an endogenous ligand that inhibits neutrophil apoptosis.

Our results also show a role for the MEK/ERK pathway following activation by S100A8/9. This pathway has been well documented to mediate signaling of both integrins and Toll-like receptors, supporting a role for CD11b, TLR4, and possibly additional receptors. This mechanism has been shown in the past to be anti-apoptotic in neutrophils via both intrinsic [46] and extrinsic [47] PCD pathways.

The correlation between beta2-integrin and TLR4 has been suggested. These two receptors may cooperate to produce signals that are transmitted into the cell. Also, TLR4 has been suggested to be an “inside-out” regulator of the beta2-integrins [48], and even a direct TLR1-beta2 integrin interaction has been suggested [49].

Other possible functional proteins that could have a “community effect” may be found in the secreted proteome of apoptotic cells. An experimental approach using 2D gel may discover additional candidate proteins and functional studies may establish their potential role in PCD.

In summary, the physiological role of S100A8/9, the most abundant cytosol protein in neutrophils, was not previously understood. We propose that at physiological protein [50] and cell concentrations, its main function is in modulating neutrophil PCD, and that cell concentration is regulated by an autocrine and paracrine mechanism via S100A8/9.

Finally, a biological “proof” is presented here, suggesting that nature encourages “community life” at the level of neutrophil survival, which could be seen as a cellular illustration for human life.

Supporting Information

Figure S1 Apoptotic neutrophils downregulate CD16.
The expression of CD16 (Fc gamma RII) on neutrophils. Freshly isolated neutrophils CD16 expression at time 0 (black line, median fluorescence of 382) and following 12 h of spontaneous PCD (gray line, median fluorescence of 35). Isotype control is shown as filled histogram.
(TIF)

Figure S2 Apoptotic neutrophils downregulate CD62L.
The expression of CD62L (L-selectin) on neutrophils. Freshly isolated neutrophils CD62L expression at time 0 (black line, median fluorescence of 791) and following 12 h of spontaneous PCD (gray line, median fluorescence of 27). Isotype control is shown as filled histogram.
(TIF)

Figure S3 Apoptosis-related proteins during spontaneous constitutive PCD in the presence of S100A8/9.
SDS-PAGE of McI1, Bcl-xl, A1, Bcl2, and survivin in spontaneous constitutive apoptosis, with and without addition of S100A8/9. McI1 (39 KD) and Bcl-xl (26 KD) were detected in all conditions. A1 (20KD) was detected from freshly isolated neutrophils but expression was downregulated significantly by spontaneous constitutive apoptosis. Addition of S100A8/9 did not rescue protein expression. Bcl2 (25KD) and survivin (19KD) were not detected under any experimental conditions. The lysates of 40x10^6 neutrophils under different conditions, including freshly isolated, after 8–10 h of spontaneous constitutive PCD, or after 8–10 h of spontaneous constitutive PCD with addition of S100A8/9, were loaded and separated by SDS-PAGE, as described in Experimental Procedures. Proteins were transferred to the PVDF membrane and exposed to the appropriate primary antibody according to manufacturers’ instructions, and then to secondary antibody conjugated with HRP.
(TIF)

Methods S1 Additional details of methods used in proteomics and programmed cell death evaluation.
(DOC)

Acknowledgments
The authors wish to thank Shifra Fraifeld, a research associate in our Medical Center, for her editorial contribution during the preparation of this manuscript.

Author Contributions
Conceived and designed the experiments: MA DM. Performed the experiments: MA AK UT SB AG IV DM. Analyzed the data: MA AK UT SB AG IV DM. Wrote the paper: MA DM.

References
1. Ellis RE, Yuan JY, Horvitz HR (1991) Mechanisms and functions of cell death. Annu Rev Cell Biol 7: 663–698.
2. Krammer PH (2000) CD95’s deadly mission in the immune system. Nature 407: 789–795.
3. Dancey JT, Deubelbeiss KA, Harker LA, Finch CA (1976) Neutrophil kinetics in man. J Clin Invest 58: 705–715.
4. Metcalf D (2008) Hematopoietic cytokines. Blood 111: 485–491.
5. Stark MA, Huo Y, Burcin TL, Morris MA, Olson TS, et al. (2005) Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17. Immunity 22: 295–294.
6. Hernandez PA, Gorlin R, Lukens JN, Taniuchi S, Bohinjec J, et al. (2003) Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. Nat Genet 34: 70–74.
7. Martin G, Burdon PC, Bridger G, Gutierrez-Ramos JC, Williams TJ, et al. (2003) Chemokines acting via CXCR2 and CXCR4 control the release of neutrophils from the bone marrow and their return following senescence. Immunity 19: 383–393.
8. Shi J, Gilbert GE, Kokubo Y, Ohashi T (2001) Role of the liver in regulating numbers of circulating neutrophils. Blood 98: 1226–1230.
9. Furze RC, Rankin SM (2008) The role of the bone marrow in neutrophil size in normal subjects and neutropenic patients as measured by epinephrine infusion. J Lab Clin Med 88: 614–620.
10. Joyce RA, Boggs DR, Hasha U, Sodes CH (1976) Marginal neutrophil pool size in normal subjects and neutropenic patients as measured by epinephrine infiltration. J Lab Clin Med 88: 614–620.
11. Iwas K, Miyawaki T, Takahara K, Konoz A, Ohka K, et al. (1994) Differential expression of bcl-2 and susceptibility to anti-Fas-mediated cell death in peripheral blood lymphocytes, monocytes, and neutrophils. Blood 84: 1201–1208.
12. Moulding DA, Quayle JA, Hart CA, Edwards SW (1998) McI-1 expression in human neutrophils: regulation by cytokines and correlation with cell survival. Blood 92: 2493–2502.
S100 A8/9 and Neutrophil Apoptosis

11. Santos-Beneit AM, Mollinedo F (2000) Expression of genes involved in initiation, regulation, and execution of apoptosis in human neutrophils and during neutrophil differentiation of HL-60 cells. J Leukoc Biol 67: 712–724.

12. Weinmann P, Gaeghtgens P, Walzog B (1999) Bcl-Xs- and Bax-alpha-mediated regulation of apoptosis of human neutrophils via caspase-3. Blood 93: 3106–3115.

13. Chuang PI, Yee E, Karnas A, Winn RK, Harlan JM (1996) A1 is a constitutive and inducible Bcl-2 homologue in mature human neutrophils. Biochem Biophys Res Commun 227: 764–771.

14. Altznauer F, Martinielli S, Youssi E, Thurig C, Schmid I, et al. (2004) Inflammation-associated cell cycle-independent block of apoptosis by survivin in terminally differentiated neutrophils. J Exp Med 199: 1343–1354.

15. Mehdling DA, Akud C, Derozet M, White MR, Edwards SW (2001) BCL-2 family expression in human neutrophils during delayed and accelerated apoptosis. J Leukoc Biol 70: 783–792.

16. Brown SB, Savill J (1999) Phagocytes trigger macrophage release of Fas ligand and antibodies to phosphatidylserine. J Exp Med 189: 1759–1768.

17. Fecho K, Cohen PI (1998) Fas ligand (gld)- and Fas (lpr)-deficient mice do not show alterations in the extravasation or apoptosis of inflammatory neutrophils. J Leukoc Biol 64: 373–383.

18. Lee WC, Keener PA, Ledbetter JA, Arulfo A, Klebanoff SJ (1996) Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J Exp Med 184: 429–440.

19. Belayev LB, Blanchard SH, Mathews R, Johnson B, McDonnell J, et al. (2002) Purified colony-stimulating factors enhance the survival of human neutrophils and eosinophils in vitro: a rapid and sensitive microassay for colony-stimulating factors. Blood 68: 162–166.

20. Colotta F, Re F, Polentarutti N, Sozzani S, Mantovani A (1992) Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood 80: 1202–2020.

21. Coxon AP, Rieu P, Barkalow FJ, Askari S, Sharpe AH, et al. (1999) A null mutation in the inflammation-associated S100 protein S100A14 causes early resorption of the mouse embryo. J Immunol 163: 2209–2216.

22. Passey RJ, Williams E, Lichanska AM, Wells C, Hu S, et al. (1999) A null mutation in the inflammation-associated S100 protein S100A14 causes early resorption of the mouse embryo. J Immunol 163: 2209–2216.

23. Mayadas TN, Calliere N (2005) Neutrophil beta2 integrins: moderators of life or death decisions. Trends Immunol 26: 388–395.

24. Roux PP, Blenis J (2004) ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 68: 320–344.

25. Dresdner I, Buckle AM, Savill JS, McDowall A, Haslett C, et al. (1994) Neutrophil apoptosis is associated with a reduction in CD16 (Fc gamma RII) expression. J Immunol 153: 1254–63.

26. Santos-Beneit AM, Mollinedo F (2000) Expression of genes involved in initiation, regulation, and execution of apoptosis in human neutrophils and during neutrophil differentiation of HL-60 cells. J Leukoc Biol 67: 712–724.

27. Weinmann P, Gaeghtgens P, Walzog B (1999) Bcl-Xs- and Bax-alpha-mediated regulation of apoptosis of human neutrophils via caspase-3. Blood 93: 3106–3115.

28. Newton RA, Hogg N (1998) The human S100 protein MRP-14 is a novel activator of the beta 2 integrin CD11b/CD18 in neutrophil apoptosis: a homeostatic mechanism in inflammation. Immunol 5: 653–666.

29. Weinmann P, Schareffetter-Kochanek K, Forlow SB, Peters T, Walzog B (2003) A role for apoptosis in the control of neutrophil homeostasis in the circulation: insights from CD18-deficient mice. Blood 101: 729–746.

30. Roux PP, Blenis J (2004) ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 68: 320–344.

31. Dresdner I, Buckle AM, Savill JS, McDowall A, Haslett C, et al. (1994) Neutrophil apoptosis is associated with a reduction in CD16 (Fc gamma RII) expression. J Immunol 153: 1254–63.

32. Kobayashi SD, Vojich JC, DeLee FR (2003) Regulation of the neutrophil-mediated inflammatory response to infection. Microbes Infect 5: 1337–1344.

33. Liu P, Kasturi E, Suda M, Itano C (1999) Accumulation and massive cell death of polymorphonuclear neutrophils in the developing bone marrow of the mouse: a histological study. Acta Anat (Basel) 153: 111–118.

34. Weinmann P, Scharffetter-Kochanek K, Forlow SB, Peters T, Walzog B (2003) A role for apoptosis in the control of neutrophil homeostasis in the circulation: insights from CD18-deficient mice. Blood 101: 729–746.

35. Roux PP, Blenis J (2004) ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 68: 320–344.

36. Dresdner I, Buckle AM, Savill JS, McDowall A, Haslett C, et al. (1994) Neutrophil apoptosis is associated with a reduction in CD16 (Fc gamma RII) expression. J Immunol 153: 1254–63.

37. Kobayashi SD, Vojich JC, DeLee FR (2003) Regulation of the neutrophil-mediated inflammatory response to infection. Microbes Infect 5: 1337–1344.

38. Liu P, Kasturi E, Suda M, Itano C (1999) Accumulation and massive cell death of polymorphonuclear neutrophils in the developing bone marrow of the mouse: a histological study. Acta Anat (Basel) 153: 111–118.

39. Frosch M, Strey A, Vogl T, Wulffraat NM, Kuis W, et al. (2000) Myeloid-related protein 14 (MRP14) results in reduced interleukin-8-induced CD11b surface expression, a polarized microfilament system, and diminished responsiveness to chemotactic agents in vitro. Mol Cell Biol 23: 1034–1043.

40. Passey RJ, Williams E, Lichanska AM, Wells C, Hu S, et al. (1999) A null mutation in the inflammation-associated S100 protein S100A14 causes early resorption of the mouse embryo. J Immunol 163: 2209–2216.

41. Ryckman C, Gilbert C, de Medicis R, Lussier A, Vandal K, et al. (2004) Monosodium urate monohydrate crystals induce the release of the proinflammatory protein S100A14/A9 from neutrophils. J Leukoc Biol 76: 433–440.

42. Odink K, Cerletti N, Bruggen J, Clerc RG, Tarsy L, et al. (1987) Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis. Nature 330: 80–82.

43. Mayadas TN, Calliere N (2005) Neutrophil beta2 integrins: moderators of life or death decisions. Trends Immunol 26: 388–395.

44. Francois S, El Benna J, Dang PM, Pedruzzi E, Gougerot-Pocidalo MA, et al. (2006) Reconstituent human granulocyte-macrophage colony-stimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression, and survival. J Clin Invest 78: 1220–1228.

45. Roux PP, Blenis J (2004) ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 68: 320–344.

46. Mollinedo F, Santos-Beneit AM (2000) Expression of genes involved in initiation, regulation, and execution of apoptosis in human neutrophils and during neutrophil differentiation of HL-60 cells. J Leukoc Biol 67: 712–724.